Overview
The Comprehensive Female II test combines saliva and dried blood spot samples to provide insights into adrenal, sex, and thyroid-related hormone levels. Saliva samples collected at multiple points capture fluctuations in cortisol throughout the day, while blood spot samples measure a range of hormones and thyroid-related markers including oestradiol, progesterone, testosterone, sex hormone binding globulin, DHEA-S, thyroid stimulating hormone, free T3, free T4, and thyroid peroxidase antibodies. This dual sampling method offers a practical way to observe hormone patterns without the need for conventional blood draws.
This test offers valuable information for individuals interested in understanding hormonal balance as it relates to energy rhythms, mood variations, sleep patterns, menstrual cycle changes, temperature regulation, or metabolic functions. By assessing multiple hormone pathways simultaneously, it supports a broader perspective on how adrenal, ovarian, and thyroid factors interact over time. The test is particularly useful for monitoring dynamic changes and providing general information, rather than focusing on any single hormone measurement.
Interpretation of the results typically takes into account factors such as menstrual cycle phase, life stage, stress levels, medications or hormone use, dietary habits, lifestyle, and other relevant wellness data. This holistic approach helps inform personal wellness strategies and supports more informed conversations about individual hormonal health. The Comprehensive Female II test encourages a comprehensive view of hormonal patterns within the context of overall wellbeing.
Comprehensive Female II is intended for informational, educational, wellness and/or research purposes only. It is not intended for use in medical diagnosis, disease screening or clinical decision-making. Comprehensive Female II is not a replacement for clinical laboratory testing and does not provide medical diagnoses. This content is intended for general information within the EU market and should not be interpreted as a regulated in-vitro diagnostic claim.
Practical
Downloads
23-Apr-2024
23-Apr-2024